Collagenase Clostridium Histolyticum Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Collagenase Clostridium Histolyticum Market Trends and Insights

Rising Prevalence and Diagnosis of Fibrotic Hand and Urological Disorders

Dupuytren's disease was reported at a 1.99% point prevalence in Dutch primary care, with an incidence of 1.72 per 1,000 person-years.^{[1]Dieuwke C. Broekstra et al., “The Incidence and Prevalence of Dupuytren's Disease in Primary Care,” Scandinavian Journal of Primary Health Care, tandfonline.com} The same study showed a higher prevalence in men and a peak among men aged 71 to 80 years. This age pattern supports sustained demand for the collagenase Clostridium histolyticum market as more patients are screened and referred for hand and urological conditions. Better diagnostic capture can increase treated volumes even where underlying disease prevalence changes slowly. The broader fibrosis burden may also keep attention on enzyme-based approaches across related conditions.

Shift Toward Minimally Invasive, Office-Based Treatment

CCH offers a non-surgical option for patients who may otherwise undergo open procedures or percutaneous needle treatment. A review of 11 studies involving 1,443 patients found comparable efficacy between CCH and percutaneous needle fasciotomy.^{[2]“Global Fibrosis Burden and a Transcriptional Biomarker-Based Strategy for Early Detection in Resource-Limited Settings,” Biomolecules, mdpi.com} Office-based administration can reduce the need for anesthesia and hospital resources. This care model fits providers seeking shorter recovery periods and lower facility use. The collagenase Clostridium histolyticum market benefits where clinicians have been trained to administer injections safely. Certification requirements can still slow the shift in areas without formal training programs.

Expansion of CCH into New Fibrotic Indications

The collagenase Clostridium histolyticum market could gain new demand if CCH receives approvals beyond its current core indications. Keenova reported positive Phase 3 results in a 436-patient plantar fibromatosis trial in July 2026. The company stated that the study met its primary endpoint for average daily pain intensity and ranked secondary endpoints related to foot function.^{[3]Keenova Therapeutics plc, “Keenova Marks 100K Peyronie's Disease Patients,” Keenova Mediaroom, mallinckrodt.mediaroom.com}The company intends to submit an FDA application in Q4 2026. Its hammer toe program also completed an End-of-Phase 2 FDA meeting, with Phase 3 enrollment planned for Q3 2026.

Increasing Specialist Familiarity and Procedure Standardization

More consistent treatment protocols can make clinicians more confident in using CCH. A Delphi-based survey on CCH treatment for Dupuytren's disease was published in the Journal of Hand Surgery Global Open in 2024. Standard protocols can improve the consistency of dosing, injection technique, and follow-up. They can also reduce training barriers for providers who are considering the treatment. In the collagenase Clostridium histolyticum market, this may strengthen payer confidence where procedure outcomes become more predictable. Updated clinical evidence for Peyronie's disease may similarly support treatment across acute and stable phases.

Serious Procedure-Related Injury and Hypersensitivity Risk

Safety concerns can affect both prescriber confidence and patient willingness to consider CCH. A 2025 review comparing CCH with limited fasciectomy reported a higher recurrence risk for CCH and identified higher rates of hematoma, local pain, and edema in several studies. Hypersensitivity reactions and the risk of tendon rupture require providers to select and monitor patients carefully. These risks may weigh more heavily in community settings with less experience in managing complications. The FDA's REMS requirements reinforce the need for trained prescribers and appropriate handling. The collagenase Clostridium histolyticum market may therefore remain concentrated in specialized settings even as new indications emerge.

High Per-Course Treatment Cost and Reimbursement Friction

High treatment cost remains a barrier where national health systems compare CCH with lower-cost surgical options. In Germany, a university hospital guide states that collagenase treatment for Dupuytren's contracture is available through import from the United States. Import dependence makes access difficult for many patients. The collagenase Clostridium histolyticum market needs reimbursement decisions that recognize any savings from reduced recovery time and avoided surgery. Without this evidence, payer restrictions may continue to limit use in Europe and emerging markets.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Indication: Dupuytren's Contracture Leads Revenue While Peyronie's Disease Grows Fastest

Dupuytren's contracture accounted for 41.72% of the 2025 collagenase Clostridium histolyticum market. Its established clinical use and broad prescriber base make it the main revenue contributor. Dutch primary-care evidence reported a 1.99% prevalence of Dupuytren's disease, with a strong association with older age. The condition is particularly relevant in North America and Northern Europe, where diagnosis pathways and trained providers are more developed. Plantar fibromatosis is an emerging opportunity rather than a current approved core use. Other potential uses include frozen shoulder and related fibrotic conditions that remain investigational.

Peyronie's disease is projected to grow at a 7.51% CAGR through 2031, the fastest rate among indications. Keenova stated in January 2026 that 100,000 Peyronie's disease patients had been treated with XIAFLEX. The condition has limited evidence-backed enzymatic alternatives, which supports the position of CCH within its approved population. Updated evidence found comparable outcomes when CCH was used in acute and stable disease phases. Earlier treatment could increase patient volumes if clinical guidance reflects this evidence. The collagenase Clostridium histolyticum market also benefits from awareness activities that reach patients and partners who may not otherwise seek care. This wider recognition may help reduce underdiagnosis in a condition that has often remained untreated.

By Formulation: Liquid Products Hold the Larger Base While Lyophilized Products Offer Faster Growth

Liquid formulations held 53.36% of the collagenase Clostridium histolyticum market in 2025. Their lead reflects established handling processes in North American and Western European clinics. Trained injection teams are accustomed to existing storage, preparation, and appointment schedules. This operational familiarity creates switching costs for providers even where clinical outcomes are comparable. Liquid products are therefore likely to retain importance in hospital and specialty clinic settings. 

Lyophilized formulations are projected to grow at an 8.36% CAGR through 2031. Their storage and distribution characteristics can be more suitable for locations with less reliable cold-chain infrastructure. Longer stability windows may also give ambulatory centers more flexibility in scheduling treatment. This can help clinics stock products closer to the point of care. The collagenase Clostridium histolyticum industry may see formulation choice become more important as treatment sites move beyond major hospital centers.

By End-User: Hospitals Retain the Largest Role While Dermatology Clinics Expand

Hospitals accounted for 46.22% of the 2025 collagenase Clostridium histolyticum market. They were early treatment sites because academic centers and orthopedic departments helped establish clinical protocols. Hospitals also have the staff and facilities needed to manage certified administration and adverse events. Ambulatory surgical centers now have a growing role as procedures become more standardized. This gradual move beyond the hospital setting can support broader access in the collagenase Clostridium histolyticum market.

Specialty clinics are forecasted to grow at a 7.92% CAGR through 2031, making them the fastest-growing end-user group. Their growth points to a broader outpatient base for injectable specialty treatments. Coverage for administration can still differ across payers and affect clinic economics. This uneven reimbursement can slow adoption even where clinicians have the necessary skills. The collagenase Clostridium histolyticum market depends on aligning referral, training, and payer processes for outpatient sites.

Geography Analysis

North America accounted for 48.26% of the collagenase Clostridium histolyticum market in 2025. The region benefits from FDA-approved treatment pathways, established specialty pharmacies, and a large trained provider base. Keenova reported USD 546.3 million in XIAFLEX net sales for FY2025 and USD 134 million for Q1 2026, which was 11% higher year over year. The United States drives regional use, while Canada and Mexico have less developed coverage for injectable treatments in these indications.

Europe has an established regulatory base but uneven patient access. The European Medicines Agency authorized XIAPEX for Dupuytren's contracture in 2011 and for Peyronie's disease in 2015. The United Kingdom and France have relatively stronger use within public health systems. Germany remains constrained because treatment may require imports from the United States. Italy's experience with more than 2,200 patients provides a sizable clinical reference for regional discussions on access.

Asia-Pacific is forecasted to grow at a 9.24% CAGR through 2031, the highest regional rate in the collagenase Clostridium histolyticum market. A 2024 study reported that the total number of treated patients fell 43%, while surgical volumes rose to 1.5 times the 2019 level. This experience indicates that demand may remain untreated when enzymatic therapy is unavailable. Regulatory progress in Japan and China, together with growing specialist communities in Australia, South Korea, and India, can support future uptake. The rest of the world, including regions like the Middle East, Africa, and South America, remains early-stage regions, with private healthcare development offset by regulatory and cold-chain constraints.